22/12/2014 07:02:53 Free Membership Login

Mylan News (NASDAQ:MYL)

DateTimeSource
Headline
12/17/20149:00AMPRNUSMylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference
Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference PR Newswire PITTSBURGH, Dec. 17, 2014 PITTSBURGH, Dec. 17, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the J.P. Morgan 33rd... More...>>
12/11/20147:30AMPRNUSMylan Launches Generic Robaxin® Injection
Mylan Launches Generic Robaxin® Injection PR Newswire PITTSBURGH, Dec. 11, 2014 PITTSBURGH, Dec. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple... More...>>
12/11/20147:00AMPRNUSMylan Launches First Generic Version of Orapred ODT®
Mylan Launches First Generic Version of Orapred ODT® - Company awarded 180 days of marketing exclusivity - PR Newswire PITTSBURGH, Dec. 11, 2014 PITTSBURGH, Dec. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg... More...>>
12/10/20147:30AMPRNUSMylan Launches One of First Available Generic Versions of Celebrex® Capsules
Mylan Launches One of First Available Generic Versions of Celebrex® Capsules PR Newswire PITTSBURGH, Dec. 10, 2014 PITTSBURGH, Dec. 10, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions... More...>>
12/08/20145:01AMPRNUSWorld TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017
World TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017 PR Newswire PITTSBURGH and NEW YORK, Dec. 8, 2014 PITTSBURGH and NEW YORK, Dec. 8, 2014 /PRNewswire/ -- World TeamTennis (WTT), the innovative leader in professional team tennis competition, and Mylan (Nasdaq: MYL), one of the world's leading... More...>>
12/04/201411:39AMPRNUSMylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration wit...
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative PR Newswire LONDON and PITTSBURGH, Dec. 4, 2014 LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced... More...>>
12/04/201411:29AMPRNCAMylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration wit...
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative Canada NewsWire LONDON and PITTSBURGH, Dec. 4, 2014 LONDON and PITTSBURGH, Dec. 4, 2014 /CNW/ -- Mylan Inc. (Nasdaq: MYL) today announced that... More...>>
12/04/201411:29AMPRNUSMylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration wit...
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative PR Newswire LONDON and PITTSBURGH, Dec. 4, 2014 LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced... More...>>
12/04/201410:00AMPRNUSMylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with...
Mylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative PR Newswire PITTSBURGH and LONDON, Dec. 4, 2014 PITTSBURGH and LONDON, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced... More...>>
12/01/20149:00PMPRNCAMylan and Canadian AIDS Society Team up in Cross-Country Relay to Accelerate Canada's Fight Against HIV/AIDS
Mylan and Canadian AIDS Society Team up in Cross-Country Relay to Accelerate Canada's Fight Against HIV/AIDS Canada NewsWire OTTAWA, Ontario, Dec. 1, 2014 OTTAWA, Ontario, Dec. 1, 2014 /CNW/ -- Mylan Inc. (Nasdaq: MYL) and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds and awareness for... More...>>
12/01/20149:00PMPRNUSMylan and Canadian AIDS Society Team up in Cross-Country Relay to Accelerate Canada's Fight Against HIV/AIDS
Mylan and Canadian AIDS Society Team up in Cross-Country Relay to Accelerate Canada's Fight Against HIV/AIDS PR Newswire OTTAWA, Ontario, Dec. 1, 2014 OTTAWA, Ontario, Dec. 1, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds and awareness... More...>>
12/01/20149:00PMPRNCAMylan et la Société canadienne du sida font équipe dans une course à relais à travers le Canada pour accélérer la lutt...
Mylan et la Société canadienne du sida font équipe dans une course à relais à travers le Canada pour accélérer la lutte contre le VIH/sida Canada NewsWire OTTAWA, le 1er déc. 2014 OTTAWA, le 1er déc. 2014 /CNW Telbec/ - Mylan (Nasdaq : MYL) et la Société canadienne du sida (SCS... More...>>
12/01/20149:00PMPRNCAMylan and Canadian AIDS Society Team up in Cross-Country Relay to Accelerate Canada's Fight Against HIV/AIDS
Mylan and Canadian AIDS Society Team up in Cross-Country Relay to Accelerate Canada's Fight Against HIV/AIDS Canada NewsWire OTTAWA, Dec. 1, 2014 OTTAWA, Dec. 1, 2014 /CNW Telbec/ - Mylan Inc. (Nasdaq: MYL) and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds and awareness for Canadians... More...>>
12/01/20147:00AMPRNUSMylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries
Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries PR Newswire PITTSBURGH and HYDERABAD, India, Dec. 1, 2014 PITTSBURGH and HYDERABAD, India, Dec. 1, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories... More...>>
11/25/20147:30AMPRNUSMylan Confirms First-to-File Patent Challenge Relating to BREVIBLOC®
Mylan Confirms First-to-File Patent Challenge Relating to BREVIBLOC® -Expects to be eligible for 180 days of marketing exclusivity- PR Newswire PITTSBURGH, Nov. 25, 2014 PITTSBURGH, Nov. 25, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it and several subsidiaries have been sued by Baxter International... More...>>
11/07/20148:00AMPRNUSMylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-...
Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors EpiPen® Auto-Injector Locations Designated on Updated Guide Maps and Signage New Multi-year Alliance to Increase Anaphylaxis Awareness through Multiple Educational Initiatives PR Newswire... More...>>
11/05/20147:30AMPRNUSMylan Launches Generic Loestrin 24 Fe®
Mylan Launches Generic Loestrin 24 Fe® PR Newswire PITTSBURGH, Nov. 5, 2014 PITTSBURGH, Nov. 5, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's... More...>>
10/30/20144:05PMPRNUSMylan Third Quarter 2014 Adjusted Diluted EPS Increases 41% to $1.16
Mylan Third Quarter 2014 Adjusted Diluted EPS Increases 41% to $1.16 2014 Adjusted Diluted EPS Guidance Range Increases to $3.54 to $3.60 PR Newswire PITTSBURGH, Oct. 30, 2014 PITTSBURGH, Oct. 30, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and nine months ended September 30... More...>>
10/30/201412:48PMPRNUSMylan Launches Generic Viramune XR®
Mylan Launches Generic Viramune XR® PR Newswire PITTSBURGH, Oct. 30, 2014 PITTSBURGH, Oct. 30, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Nevirapine Extended-release tablets, 400 mg, which is the generic version of Boehringer Ingelheim's Viramune XR®. Mylan received final approval... More...>>
10/27/20148:01AMPRNUSEpiPen4Schools® Program Enhances Support of National Movement to Improve Anaphylaxis Preparedness and Access to Emergency Tr...
EpiPen4Schools® Program Enhances Support of National Movement to Improve Anaphylaxis Preparedness and Access to Emergency Treatment in Schools Survey Findings Reveal Incidence of First-Time Reactions in School Setting PR Newswire PITTSBURGH, Oct. 27, 2014 PITTSBURGH, Oct. 27, 2014 /PRNewswire/ -- Mylan Specialty, the... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq myl141222 07:02